CC
YMAB

Corton Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

Corton Capital’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,432
Closed -$55.1K – 406
2025
Q1 		$55.1K Buy
+12,432
New +$72.2K 0.18% 157
2023
Q4 		– Sell
-12,244
Closed -$66.7K – 660
2023
Q3 		$66.7K Sell
12,244
-994
-8% -$5.79K 0.03% 404
2023
Q2 		$89.9K Buy
+13,238
New +$99.2K 0.04% 409

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Corton Capital's YMAB Position: Q2 2025 in Review

Corton Capital sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 12,432 shares — an estimated $55.1K sold.

Corton Capital first reported a position in YMAB in Q2 2023 and held it in 3 quarters. The position peaked at $89.9K in Q2 2023. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • Corton Capital reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corton Capital sold 12,432 Y-mAbs Therapeutics shares in Q2 2025, an estimated $55.1K.
  • Corton Capital first reported a position in Y-mAbs Therapeutics in Q2 2023 and held it in 3 quarters.
  • Corton Capital's Y-mAbs Therapeutics position peaked at $89.9K in Q2 2023.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.